Business Description
NuCana PLC
SIC : 2834
ISIN : US67022C1062
Share Class Description:
FRA:N04: ADRDescription
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.42 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.5 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year FCF Growth Rate | 7.7 | |||||
| 3-Year Book Growth Rate | -48.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 50.47 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.23 | |||||
| 9-Day RSI | 35.8 | |||||
| 14-Day RSI | 36.58 | |||||
| 6-1 Month Momentum % | -54.04 | |||||
| 12-1 Month Momentum % | -81.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 0.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -170.66 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -240.04 | |||||
| ROA % | -103.81 | |||||
| ROIC % | -797.38 | |||||
| ROC (Joel Greenblatt) % | -6990.12 | |||||
| ROCE % | -270.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.82 | |||||
| Price-to-Tangible-Book | 1.69 | |||||
| EV-to-EBIT | 0.26 | |||||
| EV-to-EBITDA | 0.27 | |||||
| EV-to-FCF | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 2.13 | |||||
| Earnings Yield (Greenblatt) % | 383.42 | |||||
| FCF Yield % | -329.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NuCana PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -13.784 | ||
| Beta | 1.19 | ||
| Volatility % | 77.42 | ||
| 14-Day RSI | 36.58 | ||
| 14-Day ATR (€) | 0.038002 | ||
| 20-Day SMA (€) | 1.1925 | ||
| 12-1 Month Momentum % | -81.62 | ||
| 52-Week Range (€) | 1.14 - 30 | ||
| Shares Outstanding (Mil) | 3.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NuCana PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NuCana PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NuCana PLC Frequently Asked Questions
What is NuCana PLC(FRA:N04)'s stock price today?
The current price of FRA:N04 is €1.15. The 52 week high of FRA:N04 is €30.00 and 52 week low is €1.14.
When is next earnings date of NuCana PLC(FRA:N04)?
The next earnings date of NuCana PLC(FRA:N04) is 2025-03-20 Est..
Does NuCana PLC(FRA:N04) pay dividends? If so, how much?
NuCana PLC(FRA:N04) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers